Header Logo

Connection

RACHELLE DOODY to Indans

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Indans.
RACHELLE DOODY
Connection Strength
4.579
Indans
  1. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. J Alzheimers Dis. 2017; 56(4):1495-1504.
    View in: PubMed
    Score: 0.537
  2. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res. 2012 Sep; 9(7):773-81.
    View in: PubMed
    Score: 0.398
  3. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012; 33(2-3):164-73.
    View in: PubMed
    Score: 0.389
  4. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
    View in: PubMed
    Score: 0.329
  5. Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial. Neurology. 2009 Nov 03; 73(18):1514-5; author reply 1515-6.
    View in: PubMed
    Score: 0.327
  6. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.310
  7. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
    View in: PubMed
    Score: 0.288
  8. Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
    View in: PubMed
    Score: 0.241
  9. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
    View in: PubMed
    Score: 0.183
  10. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
    View in: PubMed
    Score: 0.179
  11. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord. 1999 Nov; 13 Suppl 2:S20-6.
    View in: PubMed
    Score: 0.163
  12. Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol. 1999 Apr; 9 Suppl 2:S69-77.
    View in: PubMed
    Score: 0.157
  13. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology. 1999; 45 Suppl 1:23-32.
    View in: PubMed
    Score: 0.154
  14. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
    View in: PubMed
    Score: 0.105
  15. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 2013 May; 9(3):338-45.
    View in: PubMed
    Score: 0.100
  16. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7.
    View in: PubMed
    Score: 0.080
  17. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
    View in: PubMed
    Score: 0.073
  18. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.070
  19. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
    View in: PubMed
    Score: 0.069
  20. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005; 20(6):338-44.
    View in: PubMed
    Score: 0.061
  21. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 09; 352(23):2379-88.
    View in: PubMed
    Score: 0.060
  22. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.053
  23. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003; 64 Suppl 9:11-7.
    View in: PubMed
    Score: 0.051
  24. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14; 57(3):481-8.
    View in: PubMed
    Score: 0.046
  25. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May; 10(3):195-203.
    View in: PubMed
    Score: 0.042
  26. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
    View in: PubMed
    Score: 0.037
  27. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan; 50(1):136-45.
    View in: PubMed
    Score: 0.036
  28. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6.
    View in: PubMed
    Score: 0.022
  29. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct; 10(5):417-29.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.